At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
MM-111 + Herceptindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MM-111-02-12-02: A Phase 1 Study of MM-111 in Combination With Herceptin in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Breast Cancer
In Brief
A Phase 1 clinical trial evaluating MM-111 + Herceptin for Breast Neoplasms. Completed, enrolled 16 participants across 3 sites.
Detailed Summary
This is an open-label Phase 1 trial of MM-111 in combination with Herceptin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartApr 2010
Primary CompletionJul 2013
TodayJul 2026
First PostedApr 1, 2010
Enrollment StartApr 1, 2010
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 16.3 years ago
Interventions
MM-111 + Herceptindrug
For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV